ImpedimedASX:IPD +9.09% EV-to-EBIT is -1.12 as of Jul. 13, 2026. The stock has 6 warning signs investors should review. Among 467 Medical Devices & Instruments companies, Impedimed ranks worse than 214132.55% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Impedimed's Enterprise Value for the quarter that ended in Dec. 2025 was A$72.01 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Impedimed's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$-20.44 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Impedimed EV-to-EBIT Related Terms
Impedimed EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Impedimed's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Impedimed's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Impedimed EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Impedimed's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Impedimed's EV-to-EBIT falls into.
Impedimed's current Enterprise Value is A$22.85 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Impedimed's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$-20.44 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Impedimed (ASX:IPD) has a EV-to-EBIT of -1.12 as of Jul. 13, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Impedimed and its competitors. According to the industry distribution chart, Impedimed ranks #999999 out of 467 companies in the Medical Devices & Instruments industry.
Is Impedimed's EV-to-EBIT too high?
Impedimed's current EV-to-EBIT is -1.12. Based on the distribution chart, Impedimed ranks #999999 out of 467 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Impedimed's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Impedimed ranks #999999 out of 467 companies for EV-to-EBIT. This places Impedimed in the lower half of its industry. The industry median EV-to-EBIT is 18.49. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.49, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Impedimed and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Impedimed's current EV-to-EBIT is -1.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Impedimed stock overvalued right now?
Based on GuruFocus' analysis, Impedimed (ASX:IPD) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.08, compared to a current price of A$0.01 — trading 92.5% below its estimated fair value. The current EV-to-EBIT is -1.12. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Impedimed (ASX:IPD), the current EV-to-EBIT is -1.12 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Impedimed Ltd, together with its subsidiaries, operates in the medical devices space. The company is based in Australia and operates globally, and it generates the majority of its revenue in North America. It is engaged in developing, manufacturing, and distributing noninvasive medical devices. The company offers products that are typically used to assess and monitor lymphedema and heart failure, as well as to measure the tissue composition and fluid status of the patients. The company also offers a cloud-based digital platform (branded as SOZO) to manage patient data. The company recognises revenue from the stand-alone sale of Legacy Devices and Consumables, the Sale of SOZO Devices, and Software Subscription Services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IPD has been successfully added to your 